Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia
- PMID: 16217391
- DOI: 10.1097/01.ju.0000176459.79180.d1
Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia
Abstract
Purpose: We assessed the differential expression of survivin and other apoptotic markers in stromal and epithelial compartments of benign prostatic hyperplasia (BPH) and normal prostate tissue.
Materials and methods: Immunohistochemical staining for survivin, and transforming growth factor-beta1 and its receptors was done in normal prostate and BPH areas from 114 consecutive patients who underwent radical prostatectomy. Moreover, staining for survivin, Bcl-2, Bax, caspase-3 and Ki-67 was performed in prostate specimens from 23 consecutive patients who underwent open prostatectomy and 4 young patients who underwent cystoprostatectomy and had a normal prostate.
Results: Survivin and Bcl-2 expression increased incrementally from normal prostate to epithelial BPH to stromal BPH. Caspase-3 expression was higher in BPH epithelium than in BPH stroma, which in turn was higher than that in normal prostate. Ki-67 was significantly over expressed in BPH stroma and epithelium. Survivin expression in BPH tissue correlated with International Prostate Symptom Score, quality of life, post-void residual urine volume, maximum urine flow rate and transforming growth factor-beta1 expression.
Conclusions: Survivin is over expressed in BPH and it correlates with BPH parameters. Increases in proliferation and inhibition of apoptosis have a role in BPH.
Similar articles
-
Apoptosis profiles in benign prostatic hyperplasia: close associations of cell kinetics with percent area density of histologic composition.Urology. 2006 Oct;68(4):905-10. doi: 10.1016/j.urology.2006.05.013. Urology. 2006. PMID: 17070390
-
Resistance to apoptosis and up regulation of Bcl-2 in benign prostatic hyperplasia after androgen deprivation.J Urol. 1997 Jul;158(1):212-6. doi: 10.1097/00005392-199707000-00073. J Urol. 1997. PMID: 9186362
-
Survivin expression is associated with features of biologically aggressive prostate carcinoma.Cancer. 2004 Feb 15;100(4):751-7. doi: 10.1002/cncr.20039. Cancer. 2004. PMID: 14770431
-
[Epidemiology and natural course of benign prostatic hyperplasia].Urologe A. 1992 May;31(3):129-34. Urologe A. 1992. PMID: 1377429 Review. German.
-
Benign prostatic hyperplasia and growth factors.Urologe A. 1990 Jan;29(1):5-7. Urologe A. 1990. PMID: 1690485 Review.
Cited by
-
Role of IAPs in prostate cancer progression: immunohistochemical study in normal and pathological (benign hyperplastic, prostatic intraepithelial neoplasia and cancer) human prostate.BMC Cancer. 2010 Jan 15;10:18. doi: 10.1186/1471-2407-10-18. BMC Cancer. 2010. PMID: 20078866 Free PMC article.
-
Mechanism of RhoA regulating benign prostatic hyperplasia: RhoA-ROCK-β-catenin signaling axis and static & dynamic dual roles.Mol Med. 2023 Oct 20;29(1):139. doi: 10.1186/s10020-023-00734-2. Mol Med. 2023. PMID: 37864185 Free PMC article.
-
Y-27632 targeting ROCK1&2 modulates cell growth, fibrosis and epithelial-mesenchymal transition in hyperplastic prostate by inhibiting β-catenin pathway.Mol Biomed. 2024 Oct 26;5(1):52. doi: 10.1186/s43556-024-00216-9. Mol Biomed. 2024. PMID: 39455522 Free PMC article.
-
Evaluation of survivin expression in prostate specimens of patients with prostate adenocarcinoma and benign prostate hyperplasia underwent transurethral resection of the prostate or prostatectomy.Springerplus. 2016 May 14;5:621. doi: 10.1186/s40064-016-2283-5. eCollection 2016. Springerplus. 2016. PMID: 27330887 Free PMC article.
-
Survivin: a promising biomarker for detection and prognosis of bladder cancer.World J Urol. 2008 Feb;26(1):59-65. doi: 10.1007/s00345-007-0219-y. Epub 2007 Oct 26. World J Urol. 2008. PMID: 17962949 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials